DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+9.69%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.51B
AUM Growth
+$5.51B
(+9.2%)
Cap. Flow
+$169M
Cap. Flow
% of AUM
3.07%
Top 10 Holdings %
Top 10 Hldgs %
54.24%
Holding
168
New
43
Increased
28
Reduced
13
Closed
42
Top Buys
| 1 |
United Therapeutics
UTHR
|
$76.3M |
| 2 |
Merck
MRK
|
$67.9M |
| 3 |
Vera Therapeutics
VERA
|
$54.1M |
| 4 |
Legend Biotech
LEGN
|
$43.3M |
| 5 |
Centene
CNC
|
$27.9M |
Top Sells
| 1 |
Dynavax Technologies
DVAX
|
$67.3M |
| 2 |
Alignment Healthcare
ALHC
|
$59.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
$40.4M |
| 4 |
CMRX
Chimerix, Inc.
CMRX
|
$32.1M |
| 5 |
InMode
INMD
|
$28M |
Sector Composition
| 1 | Healthcare | 89.05% |
| 2 | Real Estate | 0.41% |
| 3 | Financials | 0% |
| 4 | Industrials | 0% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Foghorn Therapeutics
FHTX
$298M
| $15.3M | 0.28% |
3,255,514
| – | – |
|
|
ZBIO
52
Zenas BioPharma, Inc. Common Stock
ZBIO
$722M
| $15.1M | 0.27% |
1,562,942
| – | – |
|
53
NovoCure
NVCR
$1.35B
| $14.7M | 0.27% |
825,119
+175,000
| +27% | +$3.12M |
|
54
Taysha Gene Therapies
TSHA
$791M
| $12.4M | 0.23% |
+5,386,000
| New | +$12.4M |
|
55
RxSight
RXST
$364M
| $11.6M | 0.21% |
888,950
+496,618
| +127% | +$6.46M |
|
56
Delcath Systems
DCTH
$381M
| $11.1M | 0.2% |
812,561
-545
| -0.1% | -$7.41K |
|
|
OMDA
57
Omada Health, Inc. Common Stock
OMDA
$1.36B
| $10.1M | 0.18% |
+553,107
| New | +$10.1M |
|
58
Integra LifeSciences
IART
$1.18B
| $9.75M | 0.18% |
794,865
| – | – |
|
59
Spyre Therapeutics
SYRE
$1.02B
| $9.19M | 0.17% |
613,665
+163,665
| +36% | +$2.45M |
|
60
DocGo
DCGO
$152M
| $7.76M | 0.14% |
4,941,565
-109,935
| -2% | -$173K |
|
61
Structure Therapeutics
GPCR
$1.14B
| $7.74M | 0.14% |
373,407
| – | – |
|
62
Vaxcyte
PCVX
$4.17B
| $7.31M | 0.13% |
225,000
| – | – |
|
63
The Oncology Institute
TOI
$302M
| $6.89M | 0.13% |
3,360,052
| – | – |
|
64
Simulations Plus
SLP
$289M
| $6.18M | 0.11% |
354,089
| – | – |
|
65
Neuropace
NPCE
$310M
| $5.57M | 0.1% |
500,000
| – | – |
|
|
JBIO
66
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $5.31M | 0.1% |
+531,163
| New | +$5.31M |
|
67
Pulmonx
LUNG
$67.6M
| $4.9M | 0.09% |
1,890,000
| – | – |
|
|
68
Alignment Healthcare
ALHC
$3.23B
| $4.8M | 0.09% |
342,558
-4,224,915
| -93% | -$59.1M |
|
69
HilleVax
HLVX
$105M
| $3.75M | 0.07% |
1,882,654
| – | – |
|
70
CalciMedica
CALC
$45M
| $2.08M | 0.04% |
1,300,000
| – | – |
|
71
Alector
ALEC
$282M
| $1.48M | 0.03% |
1,055,192
| – | – |
|
72
Annexon
ANNX
$225M
| $1.4M | 0.03% |
583,913
| – | – |
|
73
BiomX
PHGE
$14.1M
| $1.12M | 0.02% |
2,494,108
| – | – |
|
74
Twist Bioscience
TWST
$1.57B
| $877K | 0.02% |
23,827
| – | – |
|
75
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| $742K | 0.01% |
92,787
| – | – |
|